The College of Oxford has launched a research to evaluate the protection and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in kids for the primary time, it mentioned on Saturday.
The brand new mid-stage trial will decide whether or not the vaccine is efficient on individuals between the ages of 6 and 17, based on an emailed assertion from the college.
Round 300 volunteers will probably be enrolled and first inoculations are anticipated this month, Oxford mentioned.
The 2-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ as a result of it’s cheaper and simpler to distribute than some rivals.
AstraZeneca has a goal to supply three billion doses this yr and goals to supply over 200 million doses per thirty days by April.
Canada has but to approve AstraZeneca’s vaccine.
As of Feb. 12, individuals beneath the age of 19 accounted for 16.5 per cent of circumstances (133,794) all through the nation, based on Well being Canada.